Search Within

Matthew J Matasar

  1. "Blood"
  2. "Maria Palomba"
  3. "Carol Portlock"
  4. "Craig Moskowitz"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (5)
Groups
  1. Center for Hematologic Malignancies (19)
  2. Department of Medicine (19)
  3. Hematologic Malignancies, Division of (19)
  4. Lymphoma (19)
  5. Survivorship Research (19)
  6. Population Sciences Research Program (18)

More Groups

People
  1. Andrew Zelenetz (19)
  2. Ariela Noy (19)
  3. Carol Portlock (19)
  4. Craig Moskowitz (19)
  5. David Straus (19)
  6. Maria Palomba (19)

More People

Years
  1. 2020 (1)
  2. 2019 (1)
  3. 2018 (1)
  4. 2017 (5)
  5. 2016 (3)
  6. 2015 (2)

More Years

Publications
  1. Blood (19)
Publishers
  1. American Society of Hematology (19)

Results (19)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schòˆder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Veliparib (ABT-888), bendamustine, and rituximab (VBR) is well tolerated and efficacious in patients with lymphoma: Final analysis of a phase 1b clinical trial of VB and a cohort expansion of VBR in patients with B-cell lymphoma
    Meeting Abstract

    Soumerai, J. D.; Zelenetz, A. D.; Moskowitz, C. H.; Younes, A.; Palomba, M. L.; Hamlin, P. A. Jr; Noy, A.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Defining the incidence and clinical impact of genomic alterations across different histologic types of lymphoma using a clinically validated comprehensive targeted sequencing assay
    Meeting Abstract

    Batlevi, C.; Rapaport, F.; Intlekofer, A. M.; Reiner, A.; Moskowitz, C. H.; Horwitz, S. M.; Zelenetz, A. D.; Palomba, L.; Moskowitz, A. J.; Gerecitano, J. F.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy analysis of a novel combination of the PARP inhibitor veliparib (ABT-888) plus bendamustine and rituximab in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Noy, A.; Portlock, C. S.; Palomba, M. L.; Straus, D. J.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Identification of actionable genomic alterations across different lymphoma histologies using a comprehensive next generation genomic sequencing clinical assay
    Meeting Abstract

    Batlevi, C.; Moskowitz, C. H.; Zelenetz, A. D.; Horwitz, S. M.; Palomba, L.; Gerecitano, J. F.; Copeland, A. R.; Hamlin, P.; Matasar, M. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Journal Article

    Moskowitz, C. H.; Matasar, M. J.; Zelenetz, A. D.; Nimer, S. D.; Gerecitano, J.; Hamlin, P.; Horwitz, S.; Moskowitz, A. J.; Noy, A.; Palomba, L.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant
    Meeting Abstract

    Moskowitz, A. J.; Hamlin, P. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M.; Meikle, J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Blood (2009)

    Fulltext@MSK | Save